Heat shock protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of focal adhesion kinase

Oncotarget

Volumn 3, Issue 10, 2012, Pages 1158-1168

  Flandrin Gresta, Pascale ^a,b   Solly, Françoise ^a,b   Aanei, Carmen Mariana ^a   Cornillon, Jérôme ^a   Tavernier, Emmanuelle ^a,b   Nadal, Nathalie ^a   Morteux, Franck ^b   Guyotat, Denis ^a,b   Wattel, Eric ^b   Campos, Lydia ^a,b  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

17 AAG; FAK; HSP90; MDS

Indexed keywords

CD34 ANTIGEN; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; TANESPIMYCIN;

AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CELL TRANSFORMATION; CHILD; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

EID: 84872806053     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.557     Document Type: Article

References (43)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009 Nov 5;361(19):1872-85.
2. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia. 1993 Jan;7(1):144-6.
3. Bogdanovic AD, Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia. 1997 May;11(5):656-9.
4. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Shelby Rifkin, Amna Iftikhar, Vilasini Shetty, Agapi Parcharidou, Jerome Loew, Bridget Marcus, Zaineb Khan, Colette Chaney, John Showel, Stephanie Gregory et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995 Jul 1;86(1):268-76.
5. Boudard D, Sordet O, Vasselon C, Revol V, Bertheas MF, Freyssenet D, Viallet A, Piselli S, Guyotat D, Campos L. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia. 2000 Dec;14(12):2045-51.
6. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood.2000 Dec 1;96(12):3932-8.
7. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S, Lacombe C, Dreyfus F, Mayeux P, Fontenay-Roupie M.. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood. 2002 Mar 1;99(5):1594-601.
8. Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol. 2005 Feb;166(2):557-63.
9. Boudard D, Vasselon C, Bertheas MF, Jaubert J, Mounier C, Reynaud J, Viallet A, Chautard S, Guyotat D, Campos L. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol. 2002 Jun;70(2):115-25.
10. Richter K, Haslbeck M, Buchner J. The heat shock response: life on the verge of death. Mol Cell. 2010 Oct 22;40(2):253-66.
11. Young JC, Moarefi I, Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol. 2001 Jul 23;154(2):267-73.
12. Hernandez MP, Sullivan WP, Toft DO. The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex. J Biol Chem. 2002 Oct 11;277(41):38294-304.
13. Ochel HJ, Gademann G. Heat-shock protein 90: potential involvement in the pathogenesis of malignancy and pharmacological intervention. Onkologie. 2002 Oct;25(5):466-73.
14. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003 Sep 25;425(6956):407-10.
15. Yufu Y, Nishimura J, Nawata H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res. 1992 Jun-Jul;16(6-7):597-605.
16. Flandrin P, Guyotat D, Duval A, Cornillon J, Tavernier E, Nadal N, Campos L. Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones. 2008 Sep;13(3):357-64.
17. An WG, Schulte TW, Neckers LM. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000 Jul;11(7):355-60.
18. Fumo G, Akin C, Metcalfe DD, Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood. 2004 Feb 1;103(3):1078-84.
19. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, Naoe T. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia. 2002 Aug;16(8):1535-40.
20. Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin Cancer Res. 2003 Oct 1;9(12):4483-93.
21. Grenert JP, Sullivan WP, Fadden P, Haystead TA, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 1997 Sep 19;272(38):23843-50.
22. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42(4):273-9.
23. Jego G, Hazoume A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2010 Nov 13.
24. Neckers L, Workman P. HSP90 molecular chaperone inhibitors are we ther yet ? Clin cancer res. 18 64-76.
25. Duval A, Olaru D, Campos L, Flandrin P, Nadal N, Guyotat D. Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica. 2006 May;91(5):713-4.
26. Swerdlow SH, Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., Vardiman, J.W. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. 2008.
27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189-99.
28. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A. 2003 Oct;55(2):61-70.
29. Recher C, Ysebaert L, Beyne-Rauzy O, Mansat-De Mas V, Ruidavets JB, Cariven P, Demur C, Payrastre B, Laurent G, Racaud-Sultan C. Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res. 2004 May 1;64(9):3191-7.
30. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006 Oct 1;108(7):2358-65.
31. Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 2007 Aug1;110(3):1025-8.
32. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003 Aug;14(8):1169-76.
33. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 2001 May 15;61(10):4003-9.
34. Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 2005 Jul 1;106(1):318-27.
35. George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K. Cotreatment with 17-allylaminodemethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res. 2004 May 15;64(10):3645-52.
36. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS, Jauch A, Melo JV, Fruehauf S, Zeller WJ. Synergistic activity of imatinib and 17-AAG in imatinibresistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 2005 Jul;19(7):1198-206.
37. Nimmanapalli R, O'Bryan E, Kuhn D, Yamaguchi H, Wang HG, Bhalla KN. Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAGmediated down-regulation of Akt, Raf-1, and Src kinases. Blood. 2003 Jul 1;102(1):269-75.
38. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia. 2010 Apr;24(4):699-705.
39. Walsby E, Pearce L, Burnett AK, Fegan C, Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-?B signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget. 2012 May;3(5):525-34.
40. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005 Jul 22;280(29):26729-34.
41. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005 Feb 15;105(4):1768-76.
42. Huang J, Ding T, Yang M, Liu H, Sun X, Jin J. Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells. Int J Hematol. 2011 Apr;93(4):482-93.
43. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget. 2011 Mar;2(3):209-21.